<ul>
<li>布里斯托爾 - 邁爾斯斯奎布公司的大手筆收購：在兩筆生物科技交易中投資 181 億美元</li>
</ul>
<p>Xenon Pharmaceuticals Inc.（納斯達克：XENE - 免費報告）- Cantor Fitzgerald 的研究分析師在 8 月 12 日（星期二）發佈的報告中下調了對 Xenon Pharmaceuticals 2025 財年每股收益（EPS）的預期。Cantor Fitzgerald 的分析師 J. Schimmer 現在預測該生物製藥公司 2025 財年每股收益為（$3.85），低於之前的預期（$3.43）。市場普遍預期 Xenon Pharmaceuticals 當前全年的每股收益為（$3.10）。Cantor Fitzgerald 還對 Xenon Pharmaceuticals 2026 財年的每股收益預期為（$4.08）。</p>
<p>Xenon Pharmaceuticals（納斯達克：XENE - 獲取免費報告）最近在 8 月 11 日（星期一）發佈了其財報。該生物製藥公司報告本季度每股收益為（$1.07），低於市場普遍預期的（$1.03），差額為（$0.04）。在去年同期，該公司每股收益為（$0.75）。</p>
<p>獲取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾家研究公司也最近對 XENE 發表了看法。Needham &amp; Company LLC 將 Xenon Pharmaceuticals 的目標價從$60.00 下調至$55.00，並在 5 月 13 日（星期二）的報告中給予該公司 “買入” 評級。William Blair 在 5 月 5 日（星期一）的報告中重申了對 Xenon Pharmaceuticals 股票的 “跑贏大盤” 評級。Wells Fargo &amp; Company 將 Xenon Pharmaceuticals 的目標價從$50.00 下調至$47.00，並在 5 月 13 日（星期二）的報告中給予該公司 “增持” 評級。加拿大皇家銀行在週二的研究報告中將 Xenon Pharmaceuticals 的目標價從$57.00 下調至$55.00，並給予該公司 “跑贏大盤” 評級。最後，華爾街 Zen 在 5 月 21 日（星期三）的研究報告中將 Xenon Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。一位研究分析師對該股票給予了 “賣出” 評級，而十一位分析師給予了 “買入” 評級。根據 MarketBeat 的數據，Xenon Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為$53.20。</p>
<p><strong>獲取我們關於 Xenon Pharmaceuticals 的最新報告</strong></p>
<h2>Xenon Pharmaceuticals 股票表現</h2>
<p>納斯達克 XENE 週四開盤價為$37.67。Xenon Pharmaceuticals 的 52 周低點為$26.74，52 周高點為$46.00。該股票的 50 日簡單移動平均為$32.31，200 日簡單移動平均為$34.09。該股票的市值為 29 億美元，市盈率為-10.61，貝塔值為 1.16。</p>
<h2>機構資金流入和流出</h2>
<p>一些機構投資者和對沖基金最近增加或減少了在 XENE 的持股。Geode Capital Management LLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 1.0%。Geode Capital Management LLC 目前擁有 69,529 股該生物製藥公司的股票，價值$2,726,000，此前在上個季度又購買了 720 股。Raymond James Financial Inc.在第四季度購買了 Xenon Pharmaceuticals 的新頭寸，價值約$797,000。Barclays PLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 20.9%。Barclays PLC 目前擁有 18,127 股該生物製藥公司的股票，價值$711,000，此前在上個季度又購買了 3,134 股。XTX Topco Ltd 在第四季度購買了 Xenon Pharmaceuticals 的新頭寸，價值約$316,000。最後，Walleye Capital LLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 111.5%。Walleye Capital LLC 目前擁有 221,982 股該生物製藥公司的股票，價值$8,702,000，此前在上個季度又購買了 117,022 股。機構投資者持有該公司 95.45% 的股票。</p>
<h2>Xenon Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Xenon Pharmaceuticals Inc 是一家專注於神經科學的生物製藥公司，致力於開發治療加拿大神經系統疾病患者的療法。其臨牀開發管線包括 XEN1101，這是一種新型且有效的 Kv7 鉀通道開放劑，目前正在進行針對癲癇和其他神經系統疾病的三期臨牀試驗。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Xenon Pharmaceuticals</li>
<li>REIT 股票 - 今天值得添加到您投資組合中的最佳 REIT 股票</li>
<li>數據中心為這三隻核能股票創造了看漲案例</li>
<li>什麼是日經 225 指數？</li>
<li>特斯拉的旗形圖剛剛破裂：這對股票意味着什麼</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>3 家公司將從特朗普的半導體關税中獲利</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Xenon Pharmaceuticals 嗎？</h2>
<p>在你考慮 Xenon Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Xenon Pharmaceuticals 並不在名單上。</p>
<p>雖然 Xenon Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Xenon制藥

<p>Cantor Fitzgerald 將 Xenon Pharmaceuticals (NASDAQ:XENE) 的 2025 財年每股收益（EPS）預估從（$3.43）下調至（$3.85），而市場共識預估為（$3.10）。該公司還預計 2026 財年的每股收益為（$4.08）。Xenon 報告的季度每股收益為（$1.07），未能達到預期。多位分析師已調整其目標價，平均評級為 “適度買入”，共識目標價為 $53.20。該股票開盤價為 $37.67，市值為 29 億美元，機構持股比例為 95.45%</p>

<ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>布里斯托爾 - 邁爾斯斯奎布公司的大手筆收購：在兩筆生物科技交易中投資 181 億美元</li>
</ul>
</div><p>Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report released on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the biopharmaceutical company will earn ($3.85) per share for the year, down from their previous estimate of ($3.43). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($4.08) EPS.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals Inc.（納斯達克：XENE - 免費報告）- Cantor Fitzgerald 的研究分析師在 8 月 12 日（星期二）發佈的報告中下調了對 Xenon Pharmaceuticals 2025 財年每股收益（EPS）的預期。Cantor Fitzgerald 的分析師 J. Schimmer 現在預測該生物製藥公司 2025 財年每股收益為（$3.85），低於之前的預期（$3.43）。市場普遍預期 Xenon Pharmaceuticals 當前全年的每股收益為（$3.10）。Cantor Fitzgerald 還對 Xenon Pharmaceuticals 2026 財年的每股收益預期為（$4.08）。</p>
</div><p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter in the prior year, the firm posted ($0.75) earnings per share.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals（納斯達克：XENE - 獲取免費報告）最近在 8 月 11 日（星期一）發佈了其財報。該生物製藥公司報告本季度每股收益為（$1.07），低於市場普遍預期的（$1.03），差額為（$0.04）。在去年同期，該公司每股收益為（$0.75）。</p>
</div><p>Get <strong>Xenon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other research firms have also recently weighed in on XENE. Needham &amp; Company LLC dropped their price objective on Xenon Pharmaceuticals from $60.00 to $55.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, May 13th. William Blair reiterated an &#34;outperform&#34; rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Wells Fargo &amp; Company dropped their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their target price on Xenon Pharmaceuticals from $57.00 to $55.00 and set an &#34;outperform&#34; rating for the company in a research note on Tuesday. Finally, Wall Street Zen cut Xenon Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $53.20.</p>
<div class="lb-trans"><p>其他幾家研究公司也最近對 XENE 發表了看法。Needham &amp; Company LLC 將 Xenon Pharmaceuticals 的目標價從$60.00 下調至$55.00，並在 5 月 13 日（星期二）的報告中給予該公司 “買入” 評級。William Blair 在 5 月 5 日（星期一）的報告中重申了對 Xenon Pharmaceuticals 股票的 “跑贏大盤” 評級。Wells Fargo &amp; Company 將 Xenon Pharmaceuticals 的目標價從$50.00 下調至$47.00，並在 5 月 13 日（星期二）的報告中給予該公司 “增持” 評級。加拿大皇家銀行在週二的研究報告中將 Xenon Pharmaceuticals 的目標價從$57.00 下調至$55.00，並給予該公司 “跑贏大盤” 評級。最後，華爾街 Zen 在 5 月 21 日（星期三）的研究報告中將 Xenon Pharmaceuticals 的評級從 “持有” 下調至 “賣出”。一位研究分析師對該股票給予了 “賣出” 評級，而十一位分析師給予了 “買入” 評級。根據 MarketBeat 的數據，Xenon Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為$53.20。</p>
</div><p><strong>Get Our Latest Report on Xenon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Xenon Pharmaceuticals 的最新報告</strong></p>
</div><h2>Xenon Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 股票表現</h2>
</div><p>NASDAQ XENE opened at $37.67 on Thursday. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $46.00. The stock has a 50 day simple moving average of $32.31 and a two-hundred day simple moving average of $34.09. The stock has a market cap of $2.90 billion, a P/E ratio of -10.61 and a beta of 1.16.</p>
<div class="lb-trans"><p>納斯達克 XENE 週四開盤價為$37.67。Xenon Pharmaceuticals 的 52 周低點為$26.74，52 周高點為$46.00。該股票的 50 日簡單移動平均為$32.31，200 日簡單移動平均為$34.09。該股票的市值為 29 億美元，市盈率為-10.61，貝塔值為 1.16。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in XENE. Geode Capital Management LLC increased its position in Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock valued at $2,726,000 after buying an additional 720 shares in the last quarter. Raymond James Financial Inc. bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $797,000. Barclays PLC increased its position in Xenon Pharmaceuticals by 20.9% during the 4th quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 3,134 shares in the last quarter. XTX Topco Ltd bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $316,000. Finally, Walleye Capital LLC increased its position in Xenon Pharmaceuticals by 111.5% during the 4th quarter. Walleye Capital LLC now owns 221,982 shares of the biopharmaceutical company's stock valued at $8,702,000 after buying an additional 117,022 shares in the last quarter. Institutional investors own 95.45% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近增加或減少了在 XENE 的持股。Geode Capital Management LLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 1.0%。Geode Capital Management LLC 目前擁有 69,529 股該生物製藥公司的股票，價值$2,726,000，此前在上個季度又購買了 720 股。Raymond James Financial Inc.在第四季度購買了 Xenon Pharmaceuticals 的新頭寸，價值約$797,000。Barclays PLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 20.9%。Barclays PLC 目前擁有 18,127 股該生物製藥公司的股票，價值$711,000，此前在上個季度又購買了 3,134 股。XTX Topco Ltd 在第四季度購買了 Xenon Pharmaceuticals 的新頭寸，價值約$316,000。最後，Walleye Capital LLC 在第四季度將其在 Xenon Pharmaceuticals 的持股增加了 111.5%。Walleye Capital LLC 目前擁有 221,982 股該生物製藥公司的股票，價值$8,702,000，此前在上個季度又購買了 117,022 股。機構投資者持有該公司 95.45% 的股票。</p>
</div><h2>Xenon Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals Inc 是一家專注於神經科學的生物製藥公司，致力於開發治療加拿大神經系統疾病患者的療法。其臨牀開發管線包括 XEN1101，這是一種新型且有效的 Kv7 鉀通道開放劑，目前正在進行針對癲癇和其他神經系統疾病的三期臨牀試驗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Xenon Pharmaceuticals</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Data Centers Create a Bull Case for These Nuclear 3 Stocks</li>
<li>What is the Nikkei 225 index?</li>
<li>Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>3 Companies That Will Profit From Trump's Semiconductor Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Xenon Pharmaceuticals</li>
<li>REIT 股票 - 今天值得添加到您投資組合中的最佳 REIT 股票</li>
<li>數據中心為這三隻核能股票創造了看漲案例</li>
<li>什麼是日經 225 指數？</li>
<li>特斯拉的旗形圖剛剛破裂：這對股票意味着什麼</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>3 家公司將從特朗普的半導體關税中獲利</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=XENE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Xenon Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Xenon Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Xenon Pharmaceuticals 並不在名單上。</p>
</div><p>While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Xenon Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cantor Fitzgerald 下調了 Xenon Pharma 2025 財年的每股收益預期